Smartox Biotechnology, a company based in France specialized in animal venom research, is pleased to announce a research collaboration with Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Canada, with the goal to identify venom toxins that selectively modulate specific ion channels.
The collaboration combines the expertises of Smartox Biotechnology in the study of animal venoms with Xenon Pharmaceuticals Inc.’s ion channel discovery platform. The VenomScreen® division of Smartox Biotechnology will supply venoms for in vitro screening by Xenon with the aim to identify natural toxins presenting a high selectivity for ion channels of interest.

Pursuant to the terms of the agreement, both Smartox and Xenon are free to use all intellectual properties arising out of the collaboration for internal discovery and research purposes. Smartox has an exclusive right to develop and sell venom toxins identified through the collaboration as research tools, therapeutics and diagnostics. Xenon will receive royalties on net sales for diagnostic or therapeutic products resulting from the collaboration. In addition, Smartox has granted Xenon a right as a privileged collaborator in the first negotiation concerning license or purchase agreements for the development and commercialization of any human therapeutic products.